Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Technical Know How
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 369332
Licensor grants a non-exclusive, non-transferable license to use and reproduce the Licensor Trademarks.
The Licensor Algorithm is a mathematical equation that combines scored molecular markers and clinicopathologic features. The equation may be represented as one or more equations. The equation contains parameters used to relate specific biomarkers and/or sets of biomarkers to a relevant breast cancer outcome.
Licensors sciences markers are
IHC markers ER; PGR; ERBB2 (HER2/neu); BCL2; CDKN1B (p27/Kip1); EGFR; and, TP53
FISH marker MYC
Of these, the Pre-Screening Markers are ER, PGR, ERBB2 (HER2/neu), and, the Non-Standard Markers are BCL2, CDKN1B (p27/Kip1), EGFR, TP53 MYC.
The patents are titled Diagnostic markers predictive of outcomes in breast cancer treatment and progression and methods of use thereof.
The trademark is GeneRxTM.
The Field shall mean the prognosis of breast cancers in the commercial reference laboratory space, which includes, without limitation, any facility or academic institution to the extent engaging in a commercial reference laboratory business.
IPSCIO Record ID: 4690
IPSCIO Record ID: 251135
IPSCIO Record ID: 339445
The TOP 20 model is a gene expression signature capable of predicting disease aggressiveness and prognosis in breast cancer patients. It is different from all other signatures available today because it is derived from cancer stem cells and therefore it predicts cancer behaviour based on its stem cell content. The TOP 20 genes have been defined based on published expression profiles of breast stem cells, and further selected based on their levels of expression and likelihood of reduction into practice for patient stratification in breast cancer.
IPSCIO Record ID: 315834
For the Research, Licensee shall perform primary testing associated with a validation study of its laboratory -developed test using the Licensed Technology in connection with MD Anderson Cancer Center or an equivalent academic cancer center (with the exception of tissue biopsy) including expression testing, the PSA and send-out of the PCA-3, the Validation Study. Licensee shall have the right to perform research on remnants after all testing required for the Validation Study is completed, and will be provided reasonable access to the patient data related to the applicable samples. Licensor shall obtain IRB approval for the study with MD Anderson Cancer Center by February 28, 2009 or, with an equivalent academic institution by June 30, 2009.
For the Purchasing Rights, upon issuance of FDA clearance or approval of an in vitro diagnostic kit using the Licensed Technology (IVD Kit), Licensee shall have the obligation to purchase IVD Kits for reference laboratory use from Licensorâ€™s designated manufacturer or distributor pursuant to a purchasing agreement between Licensee and the applicable manufacturer or distributor, provided however that Licensor shall negotiate to cause such manufacturer or distributor to provide Most Favored Terms to Licensee.
The patents include
Method of Identifying Patterns in Biological Systems and Uses Thereof;
Biomarkers Overexpressed in Prostate Cancer;
Biomarkers Upregulated in Prostate Cancer; and,
Methods for Screening, Predicting and Monitoring Prostate Cancer.
Licensees focus is developing a test for and performing clinical laboratory diagnostic testing using gene biomarkers detected in patient urine samples for differentiating clinically significant prostate cancer from other prostate conditions.